- Home
- SUPX vs HRMY Comparison
SUPX vs HRMY Comparison
Compare SUPX & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUPX | HRMY |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SUPX | HRMY |
|---|---|---|
| Price | $11.35 | $28.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $46.70 |
| AVG Volume (30 Days) | 253.4K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 2.71 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | N/A | $19.87 |
| Revenue Next Year | N/A | $12.49 |
| P/E Ratio | ★ N/A | $10.53 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $9.02 | $25.52 |
| 52 Week High | $76.00 | $40.87 |
Technical Indicators
Market Signals| Indicator | SUPX | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 36.97 | 32.87 |
| Support Level | $9.98 | $26.36 |
| Resistance Level | $19.09 | $37.38 |
| Average True Range (ATR) | 1.18 | 1.86 |
| MACD | -0.26 | -0.42 |
| Stochastic Oscillator | 18.24 | 23.68 |
Price Performance
Historical ComparisonAbout SUPX Super X AI Technology Limited Ordinary Shares
Super X AI Technology Ltd is an AI infrastructure solutions provider. Through its subsidiaries, SuperX offers a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, High-Voltage Direct Current (HVDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. The Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.